Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference
Nyxoah announces participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021. CEO Olivier Taelman will engage in a fireside chat at 4:00 pm CET/10:00 am ET. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA) and is known for its lead product, the Genio® system, a leadless and battery-free hypoglossal neurostimulation therapy. The company received its European CE Mark in 2019 and is currently pursuing FDA approval for its devices in the US through the DREAM IDE pivotal study.
- Successful completion of the BLAST OSA study.
- Received CE Mark for Genio® system in 2019.
- Positive outcomes from the BETTER SLEEP study leading to additional CE-Mark indication approval.
- None.
Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference
Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, with a virtual fireside chat at 4:00 pm CET/10:00 am ET.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.nyxoah.com/
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Gilmartin Group
Vivian Cervantes
IR@nyxoah.com
Attachment
